Cubist Is Latest Heptares Collaborator On GPCR-Targeted Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. acute hospital care specialist Cubist has become the sixth major pharma company to collaborate with U.K.-based Heptares on finding novel therapeutics that interact with G-protein coupled receptors.
You may also be interested in...
Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal
The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.